Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

August 1, 2025

Conditions
Tourniquet Hypertension
Interventions
DRUG

Lidocaine 2% Injectable Solution

patients received Lidocaine 2%, 1 mg/kg, IV bolus over 10 mins after the induction of anaesthesia , followed by Lidocaine infusion (2 mg/kg/h) diluted in 50 ml of normal saline with a maximum dose of 200 mg/h. The tourniquet was inflated 10 minutes after the start of the Lidocaine infusion then the Lidocaine infusion stopped at the time of tourniquet deflation

DRUG

Dexmedetomidine HCL Injection

patients received a loading dose of Dexmedetomidine-Pfizer (0.8 μg·kg-1 over 10 min) followed by continuous infusion of Dexmedetomidine (0.4 μg·kg-1.h-1) diluted in 50 ml of normal saline. The tourniquet was inflated 10 mins after the start of Dexmedetomidine infusion then the Dexmedetomidine infusion stopped at the time of the tourniquet deflation.

Trial Locations (1)

Unknown

Kasr Alainy Hospital- Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT06936410 - Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery | Biotech Hunter | Biotech Hunter